Dublin, Nov. 29, 2021 (GLOBE NEWSWIRE) -- The "Flow Cytometry Market by Product (Analyzer, Sorter, Reagents, Consumables, Software), Technology, Application (Research, Clinical - Cancer Diagnostics, Hematology), End User (Academia, Research Labs, Pharma, Biotech, Hospitals) - Global Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.
The global flow cytometry market is projected to reach USD 6.3 billion by 2026 from USD 4.3 billion in 2021, growing at a CAGR of 8.1% from 2020 to 2026.
The key factors driving the growth of this market include technological advancements in flow cytometers, the increasing adoption of flow cytometry in research and clinical trials, growing focus on immunology and immuno-oncology research, increasing incorporation of AI platforms in flow cytometry workflows and advancements in flow cytometry software, high incidence and prevalence of target diseases, and the availability of novel products.
By technology, the bead-based technology accounted for the fastest-growing segment of the flow cytometry market
By technology, the flow cytometry market is classified into cell-based and bead-based. In 2020, the cell-based flow cytometry segment accounted for the largest share of the market. However, the bead-based flow cytometry segment is expected to grow at the highest CAGR during the forecast period. The growth of the bead-based flow cytometry segment can be attributed to the procedural advantages offered by this technology over other cell-based technology, such as the capacity to detect multiple analytes (also known as multiplexing), high reproducibility, stability, and speed.
By product & service, the reagents and consumables segment accounted for the fastest-growing segment of the flow cytometry market
On the basis of product and service, the flow cytometry market is categorized into reagents and consumables, instruments, services, software, and accessories. The reagents and consumables segment is expected to witness the highest growth during the forecast period due to the development and commercialization of high-quality application-specific reagents and assays and continuous requirement of flow cytometry reagents by end users (due to the increasing number of flow cytometry-based research activities).
The Asia-Pacific to witness the highest growth during the forecast period (2021-2026)
North America is expected to hold the largest share of the global flow cytometry market in 2020 followed by Europe. However, the Asia-Pacific is expected to grow at the fastest rate during the forecast period. The increasing participation of China, India, Japan, Australia, and South Korea in flow cytometry-based research; expansion of research infrastructure in the region; and public-private finding aimed towards boosting advance research practices are the key factors responsible for the growth of this market in the Asia-Pacific.
This report studies the flow cytometry market based on technology, product and service, application, end-user, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. It analyzes opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of market segments with respect to four main regions (and the respective countries in these regions).
Rising Global Incidence and Prevalence of HIV/AIDS and Cancer
Growing Adoption of Flow Cytometry Techniques in Research & Academia
Growing Public-Private Initiatives in Immunology and Immuno-Oncology Research
Increasing Incorporation of AI Platforms in Flow Cytometry Workflow and Advancements in Flow Cytometry Software
Significant Product Costs
Growing Market Presence in the Asia-Pacific Region
Evolving Pipeline for Stem Cell Research
Adoption of Recombinant DNA Technology for Antibody Production
Evolution of Tandem Flow Cytometry Technologies
Complexities Related to Reagent Development
Dearth of Well-Trained and Skilled Professionals
Stringent FDA Requirements
Stringent Analyte-Specific Reagent Rule
Lack of Well-Defined Validation Protocols for Cell-based Assays
Absence of Established Laboratory-Developed Test Guidelines on Cell-based Fluorescence Assays
Greater Global Recognition for IVD CE Mark Approvals
US Reimbursement Scenario
Agilent Technologies, Inc.
Apogee Flow Systems Ltd.
Bay Bioscience Co. Ltd.
Becton, Dickinson and Company
Bio-Rad Laboratories, Inc.
Enzo Biochem, Inc.
Nanocellect Biomedical, Inc.
Nexcelom Bioscience LLC
On-Chip Biotechnologies Co. Ltd.
Sony Biotechnology Inc. (Subsidiary of Sony Group Corporation)
Thermo Fisher Scientific, Inc.
Union Biometrica, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/88bqsm
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900